Navigation Links
Drug Fails to Slow Progression of Atherosclerosis
Date:3/17/2009

Pactimibe also was associated with more risk of major heart problems, study finds

TUESDAY, March 17 (HealthDay News) -- A drug that blocks an enzyme involved in the accumulation of cholesterol does not reduce the progression of atherosclerosis, thickening and stiffening of the arteries, but increases the risk of major cardiovascular events, according to an international study.

Researchers assessed the safety and efficacy of the drug pactimibe, which inhibits an enzyme known as ACAT, in 892 people with a family history of high cholesterol, which is associated with an increased risk of atherosclerosis. The participants, from 40 clinics in the United States, Canada, Europe, South Africa and Israel, were randomly selected to take either 100 milligrams a day of pactimibe or a placebo, in addition to standard lipid-lowering therapy.

The researchers assessed the participants' atherosclerosis at the start of the study and 12, 18 and 24 months later using ultrasound to measure carotid intima-media thickness (CIMT), a measurement of the thickness of the inner wall of a major artery. Increasing thickness indicates increasing plaque in the artery.

After six months, levels of "bad" low-density lipoprotein (LDL) cholesterol had increased by 7.3 percent among people taking pactimibe and by 1.4 percent among those taking the placebo. This increase disappeared after participants stopped taking the drug.

There was no difference between the two groups in progression of maximum CIMT, but average CIMT progressed significantly in the pactimibe group within one year, compared with minor CIMT progression in the placebo group, the study found.

Compared with people in the placebo group, those in the pactimibe group suffered more serious events (10 percent vs. 7.7 percent) and more cardiovascular events (6.3 percent vs. 3.4 percent) and had a higher rate for the composite of cardiovascular death, heart attack and stroke (2.3 percent vs. 0.2 percent).

Dr. Marijn C. Meuwese, of the Academic Medical Center in Amsterdam, The Netherlands, and colleagues wrote that in people with a family history of cholesterol, "pactimibe had no effect on atherosclerosis as assessed by changes in maximum CIMT compared with placebo but was associated with an increase in mean CIMT as well as increased incidence of major cardiovascular events."

The findings from this and previous studies lessen "the promise and further development of this class of drugs (ACAT inhibitors) for cardiovascular prevention," they concluded.

The study is in the March 18 issue of the Journal of the American Medical Association.

More information

The U.S. National Heart, Lung, and Blood Institute has more about atherosclerosis.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, March 17, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Federal research plan to determine nanotech risks fails to deliver
2. States HMO Report Card Fails in Meaningful Evaluation of Health Care Quality and Ignores Affordability
3. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
4. Experimental Drug Fails Against Heart Failure
5. NSAID Drug Therapy Fails to Ease Back Pain
6. MedPAC Again Fails to Evaluate Overall Economic Conditions in Assessing SNF Funding Requirements
7. Steroid Fails to Ease Meningitis in Trials
8. Pharmaceutical market fails pregnant women; and more
9. Progress toward an alternative for EPO: Gas6 offers remedy where EPO fails today
10. Post-Op Chemo Fails to Boost Survival in Stomach Cancers
11. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Fails to Slow Progression of Atherosclerosis
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... expand the ability of Medicare Advantage organizations to deliver medical services via telehealth, ... , “ATA has been advocating for such language for many years. Although ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... company offering education, research and medical media, has launched Contagion® , ... infectious diseases. , As the all-inclusive resource for infectious disease information, Contagion ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on Wednesday ... , an emergency medicine professional association, to support the organization's newly established physician ... Academy of Emergency Medicine, or AAEM, seeks to empower emergency physicians to control ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Peyman Ghasri, ... now offering a variety of comprehensive procedures for facial enhancement. The treatments now ... restoration, lip enhancement and nasal reshaping. , As a result, patients can ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Gout is like ... brings pain that is often severe, with intense swelling and redness. It is triggered ... million people, but older adults are the most susceptible, according to the February 2016 ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... --  Genomic Health, Inc. (Nasdaq: GHDX ) today reported ... December 31, 2015. --> --> ... with $69.1 million in the fourth quarter of 2014, an increase ... percent compared with the same period in the prior year. ... million in the fourth quarter of 2015, an increase of 9 ...
(Date:2/10/2016)... PITTSBURGH , 10 februari 2016 ... detta pressmeddelande får inte distribueras, vare sig ... inga anmälningssedlar kommer att accepteras från eller ... där Erbjudandet, distribution av detta pressmeddelande eller ... mot tillämpliga lagar eller regler eller skulle ...
(Date:2/10/2016)... 2016 Mylan N.V. (NASDAQ, TASE: MYL) today ... ended December 31, 2015. --> ... total revenues of $9.45 billion, up 28% on a ... revenues of $9.43 billion. Excluding the impact of the ... branded generics business (the "EPD Business"), full year adjusted ...
Breaking Medicine Technology: